Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17151339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pompe disease diagnosis and management guideline

  2006cited by this paper
• Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.

  2006cited by this paper
• A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

  2006cited by this paper
• Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

  2005cited by this paper
• Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.

  2004cited by this paper
• Pediatric physical functioning reference curves.

  2004cited by this paper
• Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse.

  2004cited by this paper
• Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies.

  2003cited by this paper
• The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.

  2003cited by this paper
• Development of a disease-specific disability instrument for Pompe disease

  2003cited by this paper
• Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.

  2001cited by this paper
• Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.

  2001cited by this paper
• Towards a molecular therapy for glycogen storage disease type II (Pompe disease).

  2000cited by this paper
• Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

  2000cited by this paper
• Identification of two subtypes of infantile acid maltase deficiency.

  2000cited by this paper
• Echocardiographic assessment of ejection fraction in left ventricular hypertrophy

  1999cited by this paper
• Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.

  1999cited by this paper
• Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase.

  1997cited by this paper
• Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.

  1997cited by this paper
• Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory.

  1990cited by this paper
• Biochemical, immunological, and cell genetic studies in glycogenosis type II.

  1978cited by this paper

• Measuring What Matters to Patients with Pompe Disease: A Review of Clinical Outcome Assessments for Capturing Treatment Benefits of Innovative Novel Therapies.

  2026cites this paper
• Insights into immunogenicity and therapeutic strategies to mitigate the immune response in infantile-onset Pompe disease: a comprehensive systematic literature review

  2026cites this paper
• Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease

  2026cites this paper
• Quantitative MRI Biomarkers for Early Muscle Involvement in Late Onset Pompe Disease

  2026cites this paper
• A comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience.

  2026cites this paper
• Glycophagy: molecular mechanisms, regulatory signals, and disease associations

  2026cites this paper
• Rapid Regression of Myocardial Hypertrophy with First-Line Avalglucosidase Alfa in Infantile-Onset Pompe Disease: A Case Report.

  2026cites this paper
• Infantile-onset Pompe disease entering adulthood: insights from two decades of enzyme replacement therapy experience.

  2025cites this paper
• Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease.

  2025cites this paper
• Metabolic cardiomyopathies: untangling clinical heterogeneity with human stem-cell derived models

  2025cites this paper
• Late-onset Pompe’s disease in pediatrics: results from an Italian national survey on 38 patients and proposal of a targeted diagnostic algorithm

  2025cites this paper
• Atrioventricular Block in a Pompe Disease Patient Receiving Enzyme Replacement Therapy

  2025cites this paper
• Five-Year Outcomes of Patients with Pompe Disease Identified by the Pennsylvania Newborn Screen

  2025cites this paper
• Current and Emerging Therapies for Lysosomal Storage Disorders.

  2025cites this paper
• Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA

  2025cites this paper
• Pompe disease.

  2025cites this paper
• A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease

  2025cites this paper
• Correction of Disease Phenotype in Pompe Disease Knockout Mice Following Cationic Lipid-GL-67-Mediated Gene Therapy.

  2025cites this paper
• Management of Pompe disease alongside and beyond ERT: a narrative review

  2025cites this paper
• Successful desensitization protocol to alglucosidase and avalglucosidase alfa in a patient with infantile-onset Pompe disease

  2025cites this paper
• Engineering of a lysosomal-targeted GAA enzyme.

  2025cites this paper
• Developing Therapeutics for Rare Cardiovascular Diseases.

  2025cites this paper
• Extensive digital health technology assessment detects subtle motor impairment in mild and asymptomatic Pompe disease

  2025cites this paper
• Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice

  2025cites this paper
• Focused ultrasound delivery of enzyme replacement therapy to the brain of Gaa-/- Pompe disease mice.

  2025cites this paper
• The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.

  2025cites this paper
• Latest Advancements in Treatment Options for Infantile-Onset Pompe Disease: A Comprehensive Narrative Review

  2025cites this paper
• Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence

  2025cites this paper
• Evaluation of Muscle Disorders After Patients Have Been Placed In A Phenotypic Pattern

  2025cites this paper
• Global birth prevalence of Pompe disease: A systematic review and meta-analysis.

  2024cites this paper
• Optimizing clinical outcomes: The journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation

  2024cites this paper
• Effectiveness of Respiratory Muscle Training in Pompe Disease: A Systematic Review and Meta-Analysis

  2024cites this paper
• Neurological glycogen storage diseases and emerging therapeutics

  2024cites this paper
• Pompe disease: Unmet needs and emerging therapies.

  2024cites this paper
• A Functional Human Glycogen Debranching Enzyme Encoded by a Synthetic Gene: Its Implications for Glycogen Storage Disease Type III Management.

  2024cites this paper
• Editorial: Inborn errors of carbohydrate metabolism

  2024cites this paper
• Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.

  2024cites this paper
• Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease

  2024cites this paper
• Analyzing immune cell infiltrates in skeletal muscle of infantile-onset Pompe disease using bioinformatics and machine learning

  2024cites this paper
• Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis

  2024cites this paper
• An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation

  2024cites this paper
• Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy

  2024cites this paper
• Clinical modeling of motor function to predict treatment efficacy and enable in silico treatment comparisons in infantile‐onset Pompe disease

  2024cites this paper
• Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease

  2024cites this paper
• Failure of Autophagy in Pompe Disease

  2024cites this paper
• Real-world data of in-hospital administration of alglucosidase alfa in French patients with Pompe disease: results from the National Claims Database

  2024cites this paper
• Evaluating avalglucosidase alfa for the management of late-onset Pompe disease

  2024cites this paper
• Dose-intensive therapy (DIT) for infantile Pompe disease: A pilot study

  2024cites this paper
• Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review

  2024cites this paper
• Expert opinion on clinical presentation, diagnosis, and treatment of infantile-onset Pompe disease: a Delphi study in Türkiye

  2024cites this paper
• [Importance of early treatment and quantitative evaluation of enzyme replacement therapy for Pompe disease: alglucosidase alfa post-marketing surveillance additional analysis].

  2024cites this paper
• A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease

  2024cites this paper
• The Importance of Early Treatment of Inherited Neuromuscular Conditions

  2024cites this paper
• Novel Mutation in the Feline GAA Gene in a Cat with Glycogen Storage Disease Type II (Pompe Disease)

  2023cites this paper
• Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study

  2023cites this paper
• Speech Disorders in Children With Pompe Disease: Articulation, Resonance, and Voice Measures.

  2023cites this paper
• Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients.

  2023cites this paper
• The new horizons for treatment of Late-Onset Pompe Disease (LOPD).

  2023cites this paper
• Treatment Dilemma in Children with Late-Onset Pompe Disease

  2023cites this paper
• Outside the fiber: Endomysial stromal and capillary pathology in skeletal muscle may impede infusion therapy in infantile-onset Pompe disease.

  2023cites this paper
• Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice

  2023cites this paper
• Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis.

  2023cites this paper
• Blepharoptosis in infantile onset Pompe disease: Histological findings and surgical outcomes

  2023cites this paper
• Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.

  2023cites this paper
• Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent

  2023cites this paper
• Dose selection for biological enzyme replacement therapy indicated for inborn errors of metabolism

  2023cites this paper
• Glycogen storage diseases

  2023cites this paper
• Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort

  2023cites this paper
• Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice

  2023cites this paper
• Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry

  2023influential citation
• Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement

  2023cites this paper
• Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

  2023cites this paper
• 2023 ESC Guidelines for the management of cardiomyopathies.

  2023cites this paper
• Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants

  2023cites this paper
• Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease

  2023cites this paper
• Gene therapy for glycogen storage diseases

  2023cites this paper
• AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice

  2023cites this paper
• Current avenues of gene therapy in Pompe disease

  2023cites this paper
• Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease: From Molecular Pathophysiology to Personalized Medicine

  2023cites this paper
• Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management

  2022cites this paper
• First-in-human case report: AAV9-hGAA gene therapy for a patient with infantile-onset Pompe disease.

  2022cites this paper
• Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region

  2022cites this paper
• Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant Cohort

  2022cites this paper
• Infantile-onset Pompe disease complicated by sickle cell anemia: Case report and management considerations

  2022cites this paper
• Infantile‐onset Pompe disease with neutropenia: Treatment decisions in the face of a unique phenotype

  2022cites this paper
• The earliest enzyme replacement for infantile-onset Pompe disease in Japan.

  2022cites this paper
• Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies.

  2022cites this paper
• Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease.

  2022cites this paper
• Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism

  2022cites this paper
• IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy

  2022cites this paper
• Beyond Sarcomeric Hypertrophic Cardiomyopathy: How to Diagnose and Manage Phenocopies

  2022cites this paper
• Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation

  2022cites this paper
• A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation

  2022cites this paper
• Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein

  2022cites this paper
• Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease

  2022cites this paper
• Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease

  2022cites this paper
• To detect potential pathways and target genes in infantile Pompe patients using computational analysis

  2022cites this paper
• A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease

  2022cites this paper
• Evaluation of the butyrylcholinesterase expression and activity in CHO, HEK-293 and vero cell lines transformed by dual promoter expression vector

  2022cites this paper
• Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel

  2022cites this paper